Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib with Letrozole or Fulvestrant in Older Patients with ER+/HER2- Metastatic Breast Cancer
NCT03633331Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by Cancer and Leukemia Group B. Primary endpoint: Incidence of Adverse Events at 6 months. Started Aug 2018; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03633331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633331.